29 May 2012: May 4, 2012 the Company, together with its subsidiaries NorDiag Inc and NorDiag AB, entered into an agreement with Biotrin International Limited, Biotrin International Limited-Norwegian Branch, DiaSorin AB and DiaSorin Inc for the sale of all of the business of the Company except for activity relating to Magnatrix (instruments and reagents) and the cancer diagnostic activity carried out by Genefec. The transaction includes brand names and web address.[...]
 
Today NorDiag ASA has released the new web page: nordasa.no
The new web page include all historical investor information.
 
For further information, please contact:
Hans Hekland, Phone: +47 906 26 870
 
About NorDiag:
NorDiag is listed on the Oslo Stock Exchange with ticker NORD.

For further information - www.nordasa.no.

Read the notice in Norwegian here.